Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:CASI

CASI Pharmaceuticals 8/16/2024 Earnings Report

CASI Pharmaceuticals logo
$0.21 0.00 (0.00%)
As of 05/14/2026
ProfileEarnings HistoryForecast

CASI Pharmaceuticals EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.63
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

CASI Pharmaceuticals Revenue Results

Actual Revenue
$3.98 million
Expected Revenue
$4.43 million
Beat/Miss
Missed by -$450.00 thousand
YoY Revenue Growth
N/A

CASI Pharmaceuticals Announcement Details

Quarter
Date
8/16/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

CASI Pharmaceuticals Earnings Headlines

CASI Pharmaceuticals stock plunges on Nasdaq delisting notice
February 26, 2026  |  za.investing.comhttps://za.investing.com/news/stock-market-news/casi-pharmaceuticals-stock-plunges-on-nasdaq-delisting-notice-93CH-4132178
What Drove CASI Pharmaceuticals' 24% Rise After Hours?
February 26, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/what-drove-casi-pharmaceuticals-24-rise-after-hours/ar-AA1X6LG5
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
May 15 at 1:00 AM  |  InvestorPlace (Ad)
CASI Pharmaceuticals Fails to Renew FOLOTYN Import License in China, Halts Sales
January 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CASI/pressreleases/37197454/casi-pharmaceuticals-fails-to-renew-folotyn-import-license-in-china-halts-sales/
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection
January 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-01/67444835-casi-pharmaceuticals-announces-approval-of-clinical-trial-application-by-china-nmpa-for-phase-1-2-study-of-cid-103-for-renal-allograft-antibody-medi-200.htm
CASI Pharmaceuticals wins Nasdaq listing extension to February 2026
December 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/casi-pharmaceuticals-wins-nasdaq-listing-extension-to-february-2026/ar-AA1SVOwR
See More CASI Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CASI Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CASI Pharmaceuticals and other key companies, straight to your email.

About CASI Pharmaceuticals

CASI Pharmaceuticals (NASDAQ:CASI), Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative therapies in oncology and immunology. The company leverages a combination of small‐molecule targeted drugs and biologics to address high‐unmet medical needs in cancer and autoimmune diseases. CASI’s R&D efforts emphasize the discovery and advancement of compounds that modulate key signaling pathways, with a goal of delivering differentiated treatment options to patients worldwide.

The company’s lead clinical candidate is famitinib, a multi‐targeted tyrosine kinase inhibitor that has been evaluated in various solid tumors, including gastric, breast and renal cancers. In addition to famitinib, CASI is advancing an immuno-oncology portfolio that includes checkpoint inhibitors and novel immune modulators designed to enhance antitumor responses. Preclinical programs focus on next‐generation molecules with potential applications in both oncology and inflammatory disorders, building on the company’s proprietary discovery platform.

Founded by a team of biotech entrepreneurs and scientists, CASI Pharmaceuticals is headquartered in Beijing, with research and development operations in Shanghai and a presence in North America to support global clinical activities. The company has established strategic partnerships with academic institutions and contract research organizations to accelerate its clinical trials and expand its pipeline. CASI’s leadership team comprises industry veterans with extensive experience in drug development and regulatory affairs, guiding the company through key milestones as it pursues regulatory approvals and commercial readiness.

View CASI Pharmaceuticals Profile
Earnings Tools